(Q35784092)

10 August 2017

1 reference

title

Rosiglitazone plus metformin: combination therapy for Type 2 diabetes (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

Stefano Del Prato

1

1 reference

10 August 2017

Laura Volpe

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

1411-1422

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Unraveling the mechanism of action of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

The blooming of the French lilac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Drugs controlling triglyceride metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

Obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.6.1411

10.1517/14656566.5.6.1411

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference